Although several biomarkers such as MGMT, STAT3, and APNG have been explored to be associated with the sensitivity of TMZ (Jacinto and Esteller, 2007; Agnihotri et al., 2012; Lee et al., 2011), TMZ resistance in gliomas is still incompletely elaborated. The gene discussed is STAT3; the disease is central nervous system cancer.